Ignite Creation Date:
2024-05-06 @ 8:29 PM
Last Modification Date:
2025-12-17 @ 7:11 AM
Study NCT ID:
NCT06392763
Status:
None
Last Update Posted:
2024-04-30 00:00:00
First Post:
2024-04-26 00:00:00
Brief Title:
Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data
Status:
None
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This retrospective cohort study, based on the French medico-administrative database (SNDS), evaluated the care pathway, the effectiveness of management and the costs associated with patients treated with chimeric antigen receptor (CAR) T cells (CART-cells) (KYMRIAH or YESCARTA): paediatric and young adult patients (up to and including 25 years of age) with acute lymphoblastic leukaemia (ALL); and adult patients (18 years of age or older) with DLBCL.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None